Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 19/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288441 | 1.00 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22305297 | 0.79 | PDE3B (0.69) | PDE3BPDE3A | |
| SCHEMBL22305298 | 0.78 | PDE3B (0.65) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28634218 | 0.78 | PDE3B (0.65) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22288538 | 0.77 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL30966660 | 0.77 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL28626575 | 0.76 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL31689431 | 0.76 | PDE3B (0.58) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22288938 | 0.76 | PDE3B (0.58) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22288941 | 0.76 | PDE3B (0.58) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427153-B2 | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | claimed |
| CN-113348165-B | 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-113348165-B | 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427153-B2 | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases | CCNA1, CCNA2, CCNT2 | PDE3B 2576/4885PDE3A 2796/4885PDE4A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.